Hims & Hers Health Trading Volume Drops 33.81% to $153.7 Million Despite Stock Price Gains

On June 9, 2025, Hims & Hers Health (HIMS) saw a trading volume of $153.7 million, marking a 33.81% decrease from the previous day. The stock price rose by 0.94%, marking two consecutive days of gains and a total increase of 7.75% over the past two days.

Hims & Hers Health has been actively expanding its international footprint, particularly in Europe. The company recently announced its acquisition of Zava, a leading digital health platform in the region. This strategic move is aimed at solidifying its presence in the U.K. and expanding into other European markets, including Germany, France, and Ireland. Zava brings with it a substantial customer base of 1.3 million active users, which Hims & Hers plans to leverage to drive growth through its subscription-based model and extensive range of medications.

Hims & Hers' business model focuses on providing affordable medications directly to consumers, bypassing the traditional insurance market. This approach has resonated well with customers who prefer the convenience and cost-effectiveness of direct-to-consumer healthcare solutions. The company's success in this area has contributed to its projected revenue of over $2 billion for 2025.

In addition to its European expansion, Hims & Hers has also made significant strides in the weight loss medication market. The company recently partnered with Novo Nordisk to sell Wegovy, a popular weight loss drug, directly on its platform. This partnership is expected to boost Hims & Hers' revenue and further solidify its position in the obesity-care market.

Looking ahead, Hims & Hers aims to achieve $6.5 billion in revenue by 2030. The company's impressive gross profit margin of 77% and its focus on personalized healthcare solutions position it well for continued growth. However, investors should be aware of the regulatory risks associated with the company's aggressive business strategies.